Cholestatic liver injury is an important clinical problem with limited understanding of disease pathologies. Exosomes are small extracellular vesicles released by a variety of cells, including cholangiocytes. Exosome-mediated cell-cell communication can modulate various cellular functions by transferring a variety of intracellular components to target cells. Our recent studies indicate that the long noncoding RNA (lncRNA), H19, is mainly expressed in cholangiocytes, and its aberrant expression is associated with significant down-regulation of small heterodimer partner (SHP) P rimary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) are important chronic cholestatic liver diseases. Despite extensive research, the pathogenesis of PSC and PBC remains unknown and liver transplantation remains as the only solution.
exosomes from the primary cholangiocytes of wild-type (WT) mice suppress SHP expression in hepatocytes, but not the exosomes from the cholangiocytes of H19 2/2 mice. Furthermore, overexpression of H19 significantly suppressed SHP expression at both transcriptional and posttranscriptional levels. Importantly, transplant of H19-carrying serum exosomes of old fibrotic Mdr2 2/2 mice significantly promoted liver fibrosis (LF) in young Mdr2 2/2 mice. Conclusion: Cholangiocyte-derived exosomal-H19 plays a critical role in cholestatic liver injury. Serum exosomal H19 represents a noninvasive biomarker and potential therapeutic target for cholestatic diseases. (HEPATOLOGY 2018; 68:599-615).
P rimary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) are important chronic cholestatic liver diseases. Despite extensive research, the pathogenesis of PSC and PBC remains unknown and liver transplantation remains as the only solution.
(1) Impaired bile flow and disrupted bile acid metabolism are major contributors to cholangiopathies. (2) Our previous studies reported that taurocholate acid (TCA)-mediated activation of sphingosine 1-phosphate receptor 2 (S1PR2) not only promotes cholestatic injury in the bile duct ligation (BDL) mouse model, but also promotes the invasive growth of cholangiocarcinoma (CCA) cells. (3) (4) (5) In addition, estrogen is also a well-known risk factor for cholestasis. (6) We recently reported that estrogen-and TCAinduced aberrant expression of long noncoding RNA Abbreviations: AMPK, AMP-activated protein kinase; ANOVA, analysis of variance; Bcl-2, B-cell lymphoma 2; Bsep, bile salt export pump; CK-19, cytokeratin 19; CYP7A1, cholesterol 7 a-hydroxylase; DLS, dynamic light scattering; E2, 17b-Estradiol; ER, estrogen receptor; ERK1/2, extracellular signal-regulated kinase 1/2; FXR, farnesoid X receptor; H&E, hematoxylin and eosin; IF, immunofluorescence; LAMP, lysosomal-associated membrane protein; LF, liver fibrosis; lncRNA, long noncoding RNA; MLEs, mouse large cholangiocytes; MPH, mouse primary hepatocytes; MPC, mouse primary cholangiocytes; Mrp2, multidrug resistance-associated protein 2; MSEs, mouse small cholangiocytes; PBS, phosphate-buffered saline; p-ERK1/2, phospho-ERK1/2; PCNA, proliferating cell nuclear antigen; PSC, primary sclerosing cholangitis; S1P, sphingosine-1-phosphate; S1PR2, sphingosine 1-phosphate receptor 2; SHP, small heterodimer partner; a-SMA, a-smooth muscle actin; SphK2, sphingosine kinase 2; TCA, taurocholate; TEM, transmission electron microscopy; WT, wild type.
(lncRNA) H19, an imprinted and maternally expressed transcript, (7) was responsible for suppression of SHP expression in hepatocytes and cholestatic liver injury in multidrug resistance 2 knockout (Mdr2 2/2 ) mice. (6) However, hepatic H19 is mainly expressed in cholangiocytes, not in hepatocytes. (6) There is an important gap in understanding of how cholangiocytederived H19 impacts hepatic cholestatic injury.
Emerging evidence indicates that exosomes, the small extracellular-membrane-enclosed vesicles formed by the inward budding of endosomal membranes and released extracellularly by fusion with the plasma membrane, are important mediators of cell-to-cell communication. (8, 9) Exosomes can be released by a variety of cells under normal and pathological conditions in vitro and in vivo. (8, 10, 11) Recent studies have reported that exosome-mediated transfer of mRNAs, microRNAs, lncRNAs, proteins, and lipids is implicated in various human diseases, including liver diseases. (8, (12) (13) (14) (15) (16) It also has been shown that liver epithelial cells, both cholangiocytes and hepatocytes, are exosome-releasing cells. (17) (18) (19) (20) In addition, exosomes exist in all major body fluids, including blood, bile, and urine. (8) Biliary exosomes are involved in regulating intracellular signaling and cell proliferation in cholangiocytes. (17) Here, we demonstrate that cholangiocyte-derived exosomes are rich in H19 under cholestatic conditions. Both estrogen and TCA increase the release of H19-carrying exosomes from cholangiocytes. Cholangiocytes are the source of H19 in hepatocytes during cholestatic disease progression. In addition, H19 level in serum exosomes is correlated to severity of cholestatic liver injury in mouse cholestatic injury models and human patients with cirrhosis. We also show that H19 is a key molecule in cholangiocyte-derived exosomes that promotes cholestatic liver injury. These results suggest that H19-carrying exosomes not only can be used as noninvasive biomarkers, but also represent a potential therapeutic target for cholestatic liver diseases.
Materials and Methods

ANIMAL STUDIES
FVB and C57/BL6 wild-type (WT) mice (both male and female) were obtained from Jackson Laboratories (Bar Harbor, ME). Mdr2 2/2 mice with FVB background were gifts from Dr. Gianfranco Alpini (Texas A&M HSC College of Medicine). H19 2/2 mice (H19 D Exon1/1) with C57/BL6 background were provided by Dr. Karl Pfeifer at NIH. The H19 D Exon1/1 mouse carries a 1-kilobase deletion of H19 exon1 that removes almost the entire exon1, including the region encoding miR-675, and reduces levels of even the partial H19 transcript by >100-fold globally. (21) FVB WT and Mdr2 2/2 mice at different ages (30-100 days old) were used. C57/BL6 WT and H19 2/2 mice at 60 and 84 days old (both male and female) were used. All mice were housed in polysulfone microisolation cages maintained on a ventilated rack and cage system with one-quarter inch corn cob bedding, in a 12-hour light/12-hour dark cycle with free access to standard chow and water ad libitum. Cotton nesting pads were used for housing enrichment. For the chronic CCl 4 study, 84-day-old WT and H19 2/2 mice were gavaged with CCl 4 (1 mL/kg) or sesame oil twice a week during the light cycle as described. (22) After 8 weeks, mice were sacrificed without fasting. For in vivo exosomal studies, exosomes were isolated from serum of 100-day-old WT and Mdr2 2/2 mice (both male and female) and used to treat 50-day-old Mdr2 2/2 mice (both male and female) twice a week by tail vein injection. After 7 days, mice were sacrificed and blood and liver tissues were harvested for further analysis. All animal procedures were approved by the Virginia Commonwealth University (VCU) Institutional Animal Care and Use Committee and are also performed in accord with institutional guidelines for ethical animal studies.
HUMAN LIVER SAMPLES
Frozen human liver tissues from PSC patients and normal controls were obtained from the Liver Tissue Cell Distribution System (Minneapolis, MN), which is funded by the National Institutes of Health (contract no. HSN276201200017C).
HUMAN SERUM SAMPLES
Outpatients with compensated cirrhosis and agematched healthy controls were prospectively recruited after written informed consent. Cirrhosis was diagnosed using FibroScan, liver biopsy, or endoscopic or radiological evidence of portal hypertension in patients with chronic liver disease. None of the patients were abusing alcohol or illicit drugs, had evidence of decompensation, or were on antibiotics or probiotics or hepatitis C eradication therapy. Serum was collected and analyzed for exosomes. This protocol was approved by the Institutional Review Board of VCU.
ISOLATION OF EXOSOMES
Mouse large cholangiocytes (MLEs) and mouse small cholangiocytes (MSEs) were plated on 150-mm plates and treated with 17b-Estradiol (E2; 100 nM), TCA (0.1 mM), glycocholic acid (GCA) (0.1 mM), and deoxycholic acid (DCA) (0.05 mM) for 48 hours. Conditioned media were collected and cleared from cell debris by centrifugation at 2,000g for 15 minutes followed by 16,000g for 20 minutes at 48C. Cellderived exosomes in conditioned media were isolated by ultracentrifugation at 100,000g for 70 minutes at 48C using WX Ultra 100 from Thermo Fisher Scientific (Waltham, MA). Pellets were resuspended in sterile phosphate-buffered saline (PBS) and stored at 2808C for further analysis. For isolation of exosomes from mouse or human serum, 0.5 mL of serum was diluted with PBS to 2 mL and centrifuged at 1,200g for 15 minutes followed by 10,000g for 30 minutes at 48C. The supernatant was filtered with a 0.22-lm filter to remove all particles bigger than 200 nm followed by ultracentrifugation at 100,000g for 70 minutes at 48C. Pellets were resuspended in 50 lL of sterile PBS.
DYNAMIC LIGHT SCATTERING ANALYSIS
Isolated extracellular vesicles were resuspended with 50 lL of PBS and diluted with PBS to a 1-mL volume in a cuvette. Size and size distributions of exosomes were analyzed by dynamic light scattering (DLS) analysis using a Malvern Zetasizer Nano ZS90 series instrument (Malvern, Worcestershire, UK). All samples were measured at 258C using a 633-nm laser light set at a scattering angle of 90 degrees, following an equilibration time of 120 seconds. The analysis was carried out using the Dispersion Technology Software (v.5.10).
TRANSMISSION ELECTRON MICROSCOPY
Concentrated exosomes were fixed in 2% paraformaldehyde in PBS at room temperature for 10 minutes. Fixed exosomes were placed on formvarcarbon-coated grids (TED PELLA, Inc., Redding, CA). After being air-dried and washed with PBS, grids were immersed in 1% glutaraldehyde for 5 minutes, further contrasted, and embedded in the mixture solution of 4% uranyl acetate and 2% methyl cellulose (9:1) on ice. Following removal of the extra contrasting solution, grids were air-dried and analyzed using Zeiss Libra 120 transmission electron microscopy (TEM; Carl Zeiss, Germany) at an accelerating voltage of 100 kV.
STATISTICAL ANALYSIS
Results were obtained from at least three independent experiments and are expressed as mean 6 SD. Data were analyzed by two-tailed Student t test or one-way analysis of variance (ANOVA) with Tukey's post-hoc test using GraphPad Prism software (version 5; GraphPad Software Inc., San Diego, CA). A P value of 0.05 was considered statistically significant. Error bars indicate SD.
All other methods are described in the Supporting Information.
Results
ESTROGEN AND TCA INCREASE THE RELEASE OF EXOSOMAL H19 FROM CHOLANGIOCYTES
It is well established that both conjugated bile acids and estrogen play etiopathogenic roles in the progression and development of cholestatic liver diseases or cholangiopathies. (23) (24) (25) Our recent study showed that aberrant expression of hepatic H19 contributes to the sex disparity of cholestatic liver injury in Mdr2 2/2 mice. (6) H19 is mainly expressed in cholangiocytes, not hepatocytes. However, it is significantly up-regulated in primary mouse hepatocytes from female Mdr2 2/2 mice with severe cholestatic liver injury. (6) It is unknown how H19 is up-regulated in hepatocytes under cholestatic conditions. Exosomes are well recognized as very important cell-cell communication vehicles by their transference of various intracellular regulatory molecules (13) and can be released by both cholangiocytes and hepatocytes. (9, 26) However, it has not been determined how cholangiocyte-released exosomes play a role in estrogen-and TCA-induced cholestatic injury. We first examined the effect E2 and TCA had on exosome release in cultured MLEs. TEM and DLS analysis indicate that the size of the MLE-released exosomes is between 50 and 150 nm in diameter ( Fig. 1A-C) . Interestingly, a combination of E2 and TCA not only increased the size of the exosomes, but also increased the number of exosomes released from MLEs. Among different bile acids, only TCA slightly increased the size of exosomes in MLEs, but not in the MSEs (Supporting Fig. S1A ,B,D,E). Western blotting analysis further confirmed the expression of CD63 and lysosomal-associated membrane protein (LAMP) 1 and LAMP2, the common markers of exosomes (Fig. 1D) . We have recently reported that both E2 and TCA induced H19 expression in MLEs. (6) However, it is not clear whether MLE-released exosomes also contain H19 and whether E2-and TCA-induced increase of H19 in MLEs correlates to H19 levels in exosomes. We isolated total exosomal RNA released from the MLEs treated with E2, TCA, or both. As shown in Fig. 1E , MLE-released exosomes did contain H19 (confirmed by DNA sequencing, data not shown) and both E2 and TCA significantly and additively increased H19 levels in exosomes (Fig. 1F) . Furthermore, TCA significantly increased H19 levels in MLE-derived, but not MSE-derived, exosomes (Supporting Fig. S1C ,F). Consistent with previous studies, TCA, but not other bile acids (GCA and DCA), induced H19 upregulation both in MSE and MLE cells (Supporting Fig. S2 ).
EFFECT OF CHOLANGIOCYTE-RELEASED EXOSOMAL H19 ON SHP EXPRESSION IN HEPATOCYTES
SHP plays an important role in maintaining hepatic cholesterol and bile acid homeostasis. (27) Expression of SHP is rapidly induced by TCA in hepatocytes. (28, 29) It has been reported that hepatic overexpression of Bcell lymphoma 2 (Bcl-2) induced H19 up-regulation and rapid SHP protein degradation under cholestatic liver injury. (30) Our recent studies also found that hepatic SHP protein levels are inversely related to H19 expression levels. (6) Given that SHP and H19 are mainly expressed in hepatocytes and cholangiocytes, respectively, cholangiocyte-derived exosomes may play a critical role in transferring H19 from cholangiocytes to hepatocytes. To determine the role of H19 in regulating hepatic SHP expression, we first examined whether E2 and TCA had a direct effect on H19 expression in hepatocytes. Similar to our previous findings, H19 expression levels in normal mouse primary hepatocytes (MPHs) were very low and not induced by E2 and TCA ( Fig. 2A, left panel) . Interestingly, the purified exosomes from MLEs treated with TCA or E2 plus TCA significantly increased H19 and Bcl-2 expression in MPHs ( , and GRP78 were determined by western blotting analysis in isolated exosomes from MLE cell-culture medium and total cell lysates. (E) Representative images of the DNA agarose gels of H19 and HPRT1. (F) Relative H19 mRNA levels in isolated exosomes were determined by real-time RT-PCR and normalized using HPRT1 as an internal control. Statistical significance: *P < 0.05; **P < 0.01, compared to vehicle control group, one-way ANOVA with Tukey's post-hoc tests (n 5 3). Abbreviations: GRP78, 78-kDa glucose regulated protein; HPRT1, hypoxanthine phosphoribosyltransferase 1; MEM, modified Eagle's medium. 2/2 MPCs treated with E2 1 TCA. All mRNA levels were determined by real-time RT-PCR and normalized using HPRT1. Statistical significance: *P < 0.05; **P < 0.01; ***P < 0.001, compared to control group; ### P < 0.001, compared to E2 1 TCA group, one-way ANOVA with Tukey's post-hoc tests (n 5 3). Abbreviations: HPRT1, hypoxanthine phosphoribosyltransferase 1; shRNA, short hairpin RNA; siRNA, small interfering RNA.
MLEs, both E2 and TCA significantly induced H19 expression in MPCs (Fig. 2C) . Exosomes derived from WT MPCs treated with E2 or TCA or both significantly increased H19 levels in WT MPHs (Fig.  2D ). Interestingly, basal expression level of SHP was increased in MPHs from H19 2/2 mice compared to that in WT MPHs (Fig. 2E) . To further examine the role of cholangiocyte-derived exosomal H19 in regulating hepatic cholestatic injury, WT MPHs were treated with MPC-derived exosomes from WT or H19 2/2 mice. SHP mRNA was reduced in MPHs treated with purified exosomes from WT MPCs treated with E2 and TCA, but not with exosomes from H19 2/2 MPCs (Fig. 2F, left panel) . In addition, exosomes from WT MPCs treated with TCA or E2 plus TCA significantly increased Bcl-2 and sphingosine kinase 2 (SphK2) expression in WT MPHs, but H19 2/2 MPC-derived exosomes had no effect (Fig.  2F , right panel and Supporting Fig. S4C ). Our recent studies suggest that SphK2 is a key regulator of hepatic lipid metabolism. (31) These results indicate that cholangiocyte-derived exosomal H19 plays a critical role in regulating key genes involved in hepatic bile acid and lipid metabolism.
UP-REGULATION OF SERUM EXOSOMAL H19 LEVEL IS ASSOCIATED WITH THE SEVERITY OF CHOLESTATIC LIVER INJURY IN FIBROTIC MOUSE MODELS
The Mdr2
2/2 mouse is a well-established animal model, which mimics the disease progression of human PSC. Mdr2 2/2 mice spontaneously develop progressive biliary injury shortly after birth. (32) It also has been reported that hepatic overexpression of H19 augmented BDL-induced liver fibrosis (LF) (33) and markedly suppressed the expression of SHP. (6, 30) Our recent study demonstrates that H19 is mainly expressed in cholangiocytes, not hepatocytes. (6) Previous studies showed that exosomes shuttled mRNA, lncRNA, microRNA, lipid, and/or proteins between different cells or tissues, and the molecular constituents of exosomes are promising biomarkers of various diseases. (34, 35) In order to investigate whether cholangiocyte-derived exosomes are released into circulation, we isolated exosomes from serum of 100-day-old Mdr2 2/2 mice and sex-/age-matched FVB WT mice. The isolated serum exosomes were confirmed by western blotting analysis for exosome markers CD63, LAMP1, and LAMP2 (Fig. 3A) . Our recent study reported that H19 expression was markedly induced in liver of Mdr2 2/2 mice, especially in female Mdr2 2/2 mice. (6) We next examined whether H19 was present in serum exosomes by real-time RT-PCR. H19 level was significantly increased in serum exosomes from 100-day-old Mdr2 2/2 mice (Fig. 3B) , especially from female Mdr2 2/2 mice. Immunofluorescence (IF) staining further showed strong colocalization of CK-19 and CD63 in liver of 100-day Mdr2 2/2 mice, but not in age-matched WT mice (Fig. 3C) . To further determine whether serum exosomal H19 levels are correlated to disease progression in Mdr2 2/2 mice, we isolated serum exosomes from Mdr2 2/2 mice at different ages. Exosomal H19 levels gradually increased with progression of cholestatic liver injury in Mdr2 2/2 mice (Fig. 3D) . At the age of 30 days, H19 was undetectable in serum exosomes from both male and female Mdr2 2/2 mice. At the age of 50, 75, or 100 days, serum exosomal H19 levels were much higher in female Mdr2 2/2 mice compared to age-matched male Mdr2 2/2 mice, which was also correlated to severity of cholestatic liver injury. (6) A previous study reported that hepatic H19 expression was increased in the CCl 4 -induced LF mouse model. (30) Consistent with previous studies, both hematoxylin and eosin (H&E) and Masson's trichrome staining indicated that 8 weeks of CCl 4 administration induced severe fibrotic liver injury in WT mice (Supporting Fig. S5 ). Similarly, hepatic H19 level was markedly up-regulated in CCl 4 -treated mice (Fig. 3E, left  panel) . In addition, serum exosomal H19 levels were also increased in CCl 4 -treated mice compared to that in control groups, which is consistent with our findings in Mdr2 2/2 fibrotic models (Fig. 3E , middle and right panel). We further confirmed that serum exosomes contained the cholangiocyte marker, CK-19, indicating that cholangiocytes were the source of serum exosomes (Figs. 3D,E and Supporting Fig. S6) . Similarly, IF staining further showed strong colocalization of CK-19 and CD63 in liver of CCl 4 -administered mice, but not in control groups (Fig. 3F) .
EFFECT OF H19 OVEREXPRESSION ON CHOLANGIOCYTES AND HEPATOCYTES
In order to determine the direct effect of H19 on cholangiocytes and hepatocytes, we overexpressed H19 Statistical significance: **P < 0.01; ***P < 0.001, compared to control groups, twotailed Student t test (n 5 6). Abbreviations: GRP78, 78-kDa glucose regulated protein; HPRT1, hypoxanthine phosphoribosyltransferase 1. in MLEs and MPHs by transfection of a recombinant H19 expression plasmid. H19 was successfully overexpressed in MLEs and MPHs (Fig. 4A,D) . Overexpression of H19 not only significantly up-regulated estrogen receptor (ER) a, SphK2, Bcl-2, and a-smooth muscle actin (a-SMA) in MLE cells (Fig.  4B,C and Supporting Fig. S7 ), but also up-regulated ERa, SphK2, and Bcl-2 in MPHs (Fig. 4E,F and  Supporting Fig. S8 ). Although overexpression of H19 had no effect on farnesoid X receptor (FXR) expression (both mRNA and protein), SHP mRNA and protein expression levels were significantly suppressed by H19 in MPHs (Fig. 5A-C) . Furthermore, overexpression of H19 significantly reduced mRNA stability of SHP in MPHs (Fig. 5D) . In order to determine whether H19 had any effect on transcription of SHP, we cotransfected 293 cells with PGL4.23-SHP-promoter and H19 overexpression plasmid. SHP promoter activity was measured by luciferase assay. Overexpression of H19 suppressed SHP promoter activity (Fig. 5E, left panel) . Furthermore, purified exosomes from human normal cholangiocyte H69 overexpressing H19 also inhibited SHP promoter activity (Fig. 5E, right panel) . To further determine whether H19-mediated suppression of SHP transcription was inhibited by FXR activation, 293 cells were cotransfected with PGL4.23-SHP-promoter and pCMV-ICIS-hFXR plasmid together with transfection of H19 overexpression plasmid or treatment with exosomes isolated from H69 cells overexpressing H19 and then treated with FXR agonist GW4064. Both H19 overexpression (left panel) and exosomal H19 (right panel) inhibited SHP promoter activity under FXR activation (Fig. 5F ). These results suggest that cholangiocyte-derived H19 suppresses SHP expression at both the transcriptional and posttranscriptional levels in hepatocytes.
EFFECT OF TRANSPLANT OF SERUM EXOSOMES FROM CHOLESTATIC Mdr2 2/2 FEMALE MICE ON FIBROTIC LIVER INJURY IN VIVO
In order to further elucidate the role of exosomal H19 in promoting cholestatic liver injury in vivo, purified serum exosomes from 100-day-old female Mdr2 -exosome) were used to treat 50-day-old Mdr2 2/2 female mice by tail vein injection twice a week. The control group of mice were injected with the same amount of serum exosomes from WT mice (WTexosome). After 1 week, mice were sacrificed. Quantitative image analysis showed that IRDye 800CW NHS ester (LI-COR, NE) labeled-serum exosomes were mainly delivered to kidney and liver (Supporting Fig.  S9A ). Serum total bile acid levels were increased in Mdr2 2/2 -exosome-treated younger Mdr2 2/2 mice (Fig. 6A) , but alkaline phosphatase (ALP; Fig. 6B ), aspartate aminotransferase, and alanine aminotransferase levels were similar (Supporting Fig. 9B,C) . H&E and Masson's trichrome staining further indicated that Mdr2 2/2 -exosome-treated younger Mdr2 2/2 mice developed more severe cholestatic liver injury (Fig. 6C and Supporting Fig. S9D ), which was accompanied by up-regulation of CK-19 and proliferating cell nuclear antigen (PCNA) expression ( Fig. 6D and Supporting  Fig. S9E ). Real-time RT-PCR analysis further showed that mRNA levels of c-Myc, a-SMA, PCNA, Ki67, ERa, S1PR2, cholesterol 7 a-hydroxylase (CYP7A1; rate-limiting enzyme for bile acid synthesis), and inflammatory mediators (tumor necrosis factor alpha, interleukin [IL]-1b, and IL-10) were significantly increased, but mRNA levels of SHP, bile salt export pump (Bsep), and multidrug resistance-associated protein 2 (Mrp2) were markedly decreased in Mdr2 2/2 -exosome-treated younger Mdr2 2/2 mice ( Fig. 6E and Supporting Fig. S10A ). mRNA level of organic solute transporter beta was decreased, but mRNA level of Mrp3 was similar in Mdr2 2/2 -exosome-treated younger Mdr2 2/2 mice (Supporting Fig. 10B,C) . Interestingly, although FXR protein level was not changed, SHP protein level was significantly decreased in Mdr2 2/2 -exosome-treated younger Mdr2 2/2 mice (Fig. 6F ). In addition, protein levels of c-Myc, S1PR2, and SphK2 were also significantly increased in Mdr2 2/2 -exosome-treated younger Mdr2 2/2 mice (Fig. 6F) . SHP levels in liver of Mdr2 2/2 mice treated with PBS or WT-exosomes remained the same (Supporting Fig. S10D ). These results suggest that cholangiocyte-derived exosomal H19 is a key player in promoting cholestatic liver injury.
HEPATIC H19 IS UP-REGULATED IN HUMAN PSC PATIENTS
Given that the exosomes carrying H19 contribute to cholestatic liver injury, H19 expression levels in serum exosomes could be a useful and critical marker of prognosis in cholestatic liver injury. To test this hypothesis, we first examined the expression of H19 in the liver of human PSC patients to determine its clinical relevance. H19 expression levels were markedly increased Relative luciferase activity of SHP promotor was measured and normalized with protein content. Statistical significance: *P < 0.05; **P < 0.01; ***P < 0.001, compared to control groups; ## P < 0.01; ### P < 0.001, compared to control 1 GW4064 group, two-tailed Student t test (D,E), one-way ANOVA with Tukey's post-hoc tests (A,C,F; n 5 3). Abbreviations: CP, control plasmid; Exos, exosomes; HPRT1, hypoxanthine phosphoribosyltransferase 1; NC, negative control.
FIG. 6. Effect of transplant of serum exosomes from cholestatic Mdr2
2/2 female mice on fibrotic liver injury in vivo. Serum exosomes were isolated from 100-day-old WT (control group) or Mdr2 2/2 mice (exosomes group) and used to treat 50-day-old Mdr2 Relative mRNA levels of c-Myc, a-SMA, PCNA, Ki67, SHP, CYP7A1, Besp, Mrp2, ERa, and S1PR2 were determined by real-time RT-PCR and normalized using HPRT1 as an internal control. (F) Representative immunoblotting images and relative protein levels of c-Myc, FXR, SHP, S1PR2, SphK2, and normalized using b-Actin as a loading control. Scale bar 5 100 lm. Statistical significance: *P < 0.05; **P < 0.01; ***P < 0.01, compared to control group, two-tailed Student t test (n 5 4). Abbreviation: HPRT1, hypoxanthine phosphoribosyltransferase 1. in the liver of human PSC patients (Fig. 7A) . Consistent with our findings in Mdr2 2/2 mice, CD63 expression was also up-regulated in the liver of human PSC patients (Fig. 7B) . Our recent studies in Mdr2 2/ 2 mice indicated that up-regulation of hepatic H19 under cholestatic conditions is associated with activation of extracellular signal-regulated kinase 1/2 (ERK1/2), up-regulation of c-Myc, S1PR2, and SphK2, and down-regulation of FXR and SHP. (6) Similarly, phospho-ERK1/2 (p-ERK1/2), c-Myc, FIG. 7 . Hepatic expression levels of H19 and related genes in human PSC patients and serum exosomes from patients with cirrhosis. Total RNA was extracted from frozen liver tissues of normal control and PSC patients. Relative mRNA levels of H19 (A) and CD63 (B) were determined by real-time RT-PCR and normalized using HPRT1 as an internal control. (C) Representative immunoblotting images and relative protein expression levels of c-Myc, p-ERK1/2, FXR, SHP, S1PR2, and SphK2 were normalized using t-ERK1/2 or b-Actin as a loading control. (D-F) Serum exosomes were isolated from normal controls and patients with cirrhosis as described in Materials and Methods. Relative mRNA levels of H19, CK-19, and CD63 were determined by real-time RT-PCR and normalized using 18srRNA as an internal control. Representative DNA agarose gels of H19, CK-19, CD63, and 18srRNA are shown. Statistical significance: *P < 0.05; **P < 0.01; ***P < 0.001, compared to normal control, two-tailed Student t test (PSC liver samples, n 5 16; patient with cirrhosis serum, n 5 9). Abbreviations: HPRT1, hypoxanthine phosphoribosyltransferase 1; t-ERK1/2, total ERK1/2. S1PR2, and SphK2 protein levels are significantly increased, but FXR and SHP protein levels are markedly down-regulated, in human PSC livers (Fig. 7C) .
To further examine the correlation of serum exosomal H19 levels with fibrotic liver injury, we isolated serum exosomes from human patients with compensated cirrhosis and age-/sex-matched normal controls. Isolation of exosomes was confirmed by real-time PCR for CD63 expression (Fig. 7F) . Similar to the findings in Mdr2 2/2 mice, H19 levels were significantly increased in serum exosomes from patients with cirrhosis (Fig. 7D) . In addition, CK-19 level was also increased, indicating cholangiocyte-released exosomes (Fig. 7E) .
Discussion
Cholangiocytes are the primary target of cholestatic liver injury. Accumulation of bile acids in the liver activates the inflammatory response, which results in the destruction of intrahepatic bile ducts and eventually leads to cholangitis, fibrosis, and potentially cirrhosis. (2) It has been well documented that in addition to bile acids, estrogen also contributes significantly in promoting cholangiocyte proliferation, a typical hallmark influencing disease progression of cholangiopathies. (36, 37) Interestingly, our recent results showed that TCA/S1PR2-and estrogen-induced up-regulation of H19 in cholangiocytes is correlated with the sex disparity of cholestatic liver injury in Mdr2 2/2 mice. (6) We also showed that aberrant expression of H19 contributes to dysregulation of hepatic bile acid metabolism through suppression of SHP expression in hepatocytes. (6) However, it remains unclear how cholangiocyte-derived H19 regulates bile acid metabolism in hepatocytes. In the current study, we show that cholangiocyte-derived H19-carrying exosomes are responsible for TCA-and estrogen-mediated suppression of hepatic SHP expression and cholestatic liver injury.
Intercellular communication is critical for maintenance of physiological homeostasis for multicellular organisms. In addition to direct cell-to-cell contact, cells also communicate by sending and receiving regulatory signals. These signals can be from the environment or from other cells. As mediators of cell communication, exosomes have recently garnered much attention for their vital role not only in normal physiological homeostasis, but also in the pathogenesis of various human diseases, such as metabolic diseases, liver diseases, and cancers. (10, 38, 39) Exosomes can be released by many different types of cells, including dendritic cells, macrophages, lymphocytes, hepatocytes, cholangiocytes, mast cells, and tumor cells, and can transfer various signaling molecules, including protein, DNA, mRNA, microRNA, lncRNA, and lipids, between neighboring and distant cells. (13, 16, 40) Exosomes also have been identified in various biofluids, including serum, bile, urine, breast milk, lymph, saliva, and malignant ascites, suggesting their potential impact on multiple organ systems. (40, 41) Accumulating evidence indicates that liver-derived exosomes are closely associated with hepatic inflammation, stress response, apoptosis, and fibrosis. (38) Studies done by Masyuk et al. reported that biliary exosomes regulate microRNA expression and intracellular signaling pathways and promote cholangiocyte proliferation through interaction with primary cilia. (17) It has been reported that an increase in circulating exosomes is associated with disease states of obesity-related metabolic diseases, including insulin resistance, diabetes, nonalcoholic fatty liver disease, and nonalcoholic steatohepatitis. (38) A recent study identified proteomic signatures in serum exosomes of CCA, PSC, and hepatocellular carcinoma patients. (42) Several studies have reported that hepatocyte-derived exosomes are involved in drug-induced liver injury, alcoholic liver disease, lipid-induced hepatic injury, and viral hepatitis C infection. (16, 20, (43) (44) (45) However, the role of cholangiocyte-derived exosomes in cholangiopathies remains largely unknown.
In the present study, we report that cholangiocytederived exosomes transfer lncRNA H19 into hepatocytes. Our recent studies identify that H19 is mainly expressed in cholangiocytes and aberrant expression of H19 is correlated to suppression of hepatic SHP expression, activation of hepatic inflammation, and severe cholestatic liver injury. (6) H19 is an estrogenregulated gene and is identified as a breast tumor oncogene. (46) Aberrant expression of H19 was also observed in CCl 4 -induced cirrhosis and BDL-induced fibrosis. (30) We further showed that the expression level of H19 was not only increased in liver, but also significantly increased in serum exosomes in CCl 4 -administered mice (Fig. 3) . Similar to our previous findings that TCA and E2 induced H19 expression in MLE cells, (6) TCA and E2 also increased H19 levels in large cholangiocyte-derived (Fig. 1E,F) , but not in small cholangiocyte-derived, exosomes (Supporting Fig. S1 ). The in vivo transplant of serum-derived exosomes from old Mdr2 2/2 mice with severe cholestatic liver injury into young Mdr2 2/2 mice with benign liver injury significantly promoted fibrotic liver injury (Fig.  6 ), but had no effect on WT mice (data not shown). Serum exosomes often contain the markers of cell origin. Serum exosomes from Mdr2 2/2 mice and CCl 4 -administered mice both contained significant amounts of CK-19, indicating a cholangiocyte origin (Fig.  3D,E) . Similarly, serum exosomes from human patients with cirrhosis not only contained higher H19, but also contained CK-19 (Fig. 7) . Our data suggest that cholangiocyte-released H19-carrying exosomes also do not initiate cholestatic liver injury, but play a critical role in promoting cholestatic liver injury in Mdr2 2/2 mice, CCl 4 -treated mice, and patients with cirrhosis. As expected, H19 levels in serum exosomes of Mdr2 2/2 mice were gradually increased during disease progression (Fig. 3D) , suggesting that H19 in serum exosomes can be used as a diagnostic biomarker for assessing cholestatic injury.
Recently, it has been reported that hepatocyte-released exosomes promote hepatocyte proliferation in vitro and liver regeneration in vivo by mediating transfer of SphK2 into target cells and inducing up-regulation of intracellular sphingosine-1-phosphate (S1P). (47) In the current study, we also found that overexpression of H19 induced SphK2 expression both in cholangiocytes and hepatocytes (Fig. 4B,E) . Hepatic SphK2 expression levels are also increased in cholestatic Mdr2 2/2 mice and human PSC patients (Figs. 6F and 7C) . Furthermore, we show that TCA and E2 significantly increased S1P levels in cholangiocyte-derived exosomes (Supporting Fig. S11 ). Although S1P itself did not induce H19 expression in hepatocytes, it enhanced exosome-induced H19 transfer (data not shown). It also has been reported that activation of S1P receptors is essential for cargo sorting into multivesicular endosomes for exosomal release. (48) However, the underlying mechanisms of exosome formation, targeting, and function remain largely unknown.
FIG. 8.
Schematic diagram of proposed mechanisms by which cholangiocyte-derived H19-carrying exosomes promote cholestatic liver injury. H19 is mainly expressed in cholangiocytes. In cholangiocytes, TCA/S1PR2-and E2-induced activation of ERK1/2 upregulates H19 expression level and promotes H19-carrying exosome release. Cholangiocyte-derived exosomes deliver H19 to hepatocytes directly or by circulation. Uptake of H19-carrying exosomes from cholangiocytes suppresses SHP expression by inhibiting promotor activity and destabilizing SHP mRNA in hepatocytes. In addition, TCA-and E2-induced activation of ERK1/2 in hepatocytes also activates AMPK, which further inhibits SHP transcription. Down-regulation of SHP expression results in increase of bile acid synthesis and eventually causes cholestatic liver injury.
We previously reported that E2 and TCA induced H19 expression through TCA/S1PR2-and estrogen/ ER-mediated activation of the ERK1/2 signaling pathway in cholangiocytes. (6) In the current study, we showed that E2 and TCA promoted exosomal release from cholangiocytes and enriched the content of H19 in exosomal cargo (Fig. 1) . Similar to our findings in Mdr2 2/2 mice, (6) the hepatic ERK1/2 signaling pathway is highly activated in human PSC patients, which is accompanied by down-regulation of FXR and SHP and up-regulation of S1PR2 and SphK2 (Fig. 7C) . Recent studies by Zhang et al. reported that overexpression of Bcl-2 significantly induced hepatic H19 expression. Down-regulation of H19 or overexpression of SHP rescued Bcl-2 overexpression-induced hepatic injury. (30) In the current study, we further show that TCA-induced H19 expression in cholangiocytes plays a vital role in regulating hepatic SHP expression and cholestatic liver injury. The basal expression level of SHP is increased in H19 2/2 mice (Fig. 2E ). TCAinduced SHP expression is markedly suppressed by cholangiocyte-derived exosomal H19 (Fig. 2B) .
In conclusion, together with our previous studies, we elucidated important mechanisms underlying cholestatic liver injury. As summarized in Fig. 8 , under cholestatic conditions, TCA-and estrogen-induced activation of ERK1/2 signaling pathways by their cognate receptors up-regulates H19 expression in cholangiocytes and exosomal release. H19-carrying exosomes can be delivered to hepatocytes and other target cells by circulation. In hepatocytes, exosomal H19 suppresses SHP expression by inhibiting promotor activity and reducing mRNA stability. TCA-/estrogen-induced ERK1/2 activation in hepatocytes also can suppress SHP expression through activation of AMP-activated protein kinase (AMPK). (24) In addition to its regulatory role in bile acid and lipid metabolism, SHP has also been identified as an important regulator of innate immune response and an intrinsic negative regulator of the nucleotide-binding oligomerization domain-, leucine-rich repeat-and pyrin domaincontaining 3 inflammasome to prevent an excessive inflammatory response. (49) Collectively, our findings highlight a mode of communication between cholangiocytes and hepatocytes and attribute a function for exosomes in the regulation of hepatic bile acid and lipid homeostasis. This study also contributes to the understanding of disease progression of cholangiopathies. In addition to direct interaction between cholangiocytes and hepatocytes and other soluble factors released by cholangiocytes, exosomes can transfer H19, lipids, and other cytosolic components into hepatocytes and participate in the homeostasis of hepatic bile acids and lipids. These studies not only identified a serum biomarker for cholestatic liver diseases, but also suggested a path for strategies to treat cholangiopathies by manipulating the contents of cholangiocyte-derived exosomes.
